Shopping Cart (0)
My Account

 Shopping Cart
Conferences | Training Courses | Market Reports | Managed Events | Past Conferences | Update Me
SELECTBIO Conferences Biofluid Biopsies
Conferences  \  Biofluid Biopsies & High-Value Diagnostics 2015  \  Biofluid Biopsies  \  Agenda  \  Hsian-Rong Tseng
RegisterLogin

Hsian-Rong Tseng's Biography


Hsian-Rong Tseng, Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute, University of California-Los Angeles

Dr. Tseng is professor in the Department of Molecular & Medical Pharmacology at UCLA. He also holds memberships of the California NanoSystems Institute, Crump Institute for Molecular Imaging and Institute for Molecular Medicine on the UCLA campus. Since he joined UCLA Pharmacology in 2003, Dr. Tseng’s group at UCLA has developed a series of nanotechnology- and microfluidics-enabled in vitro molecular diagnostic (IVMD) technologies. In collaboration with his physician colleagues, the goal of their joint team is to translate these new IVMD technologies from research bench to clinical practice.

Hsian-Rong Tseng Image

NanoVelcro-Embedded Microchips for Detection and Characterization of Circulating Tumor Cells

Tuesday, 17 November 2015 at 09:00

Add to Calendar ▼2015-11-17 09:00:002015-11-17 10:00:00Europe/LondonNanoVelcro-Embedded Microchips for Detection and Characterization of Circulating Tumor CellsSELECTBIOenquiries@selectbiosciences.com

Inspired by the nanoscale interactions observed in the tissue microenvironment, our research team at UCLA pioneered a unique concept of “NanoVelcro” cell-affinity substrates, in which CTC capture agent-coated nanostructured substrates were utilized to immobilize CTCs with high efficiency. The working mechanism of NanoVelcro cell-affinity substrates mimics that of VelcroTM – when the two fabric strips of a Velcro fastener are pressed together, tangling between the hairy surfaces on two strips leads to strong binding.  Through continuous evolution, 3 generations of NanoVelcro CTC Chips have been established to achieve different clinical utilities. My presentation will summarize the continuous evolution of NanoVelcro CTC Assays from the emerge of the original idea all the way to their applications in cancer research and diagnosis. We envision that NanoVelcro CTC Assays will lead the way for powerful and cost-efficient diagnostic platforms for researchers to better understand underlying disease mechanisms and for physicians to monitor real-time disease progression.

Add to Calendar ▼2015-11-16 00:00:002015-11-17 00:00:00Europe/LondonBiofluid BiopsiesSELECTBIOenquiries@selectbiosciences.com


Corporate Sponsors